Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot
This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot: STU1 Ballot 1) based on FHIR (HL7® FHIR® Standard) v5.0.0. . For a full list of available versions, see the Directory of published versions
<Group xmlns="http://hl7.org/fhir">
<id value="179785"/>
<meta>
<versionId value="4"/>
<lastUpdated value="2023-12-04T20:30:06.799Z"/>
<profile
value="http://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-definition"/>
</meta>
<text>
<status value="extensions"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative: Group</b><a name="179785"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Resource Group "179785" Version "4" Updated "2023-12-04 20:30:06+0000" </p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-comparator-definition.html">ComparatorDefinition</a></p></div><p><b>Artifact related artifact</b>: </p><p><b>Artifact Title</b>: ComparatorDefinition: Usual-care pharmacologic thromboprophylaxis</p><p><b>Artifact URL</b>: <a href="https://fevir.net/resources/Group/179785">https://fevir.net/resources/Group/179785</a></p><p><b>Artifact Publisher</b>: Computable Publishing LLC</p><p><b>Artifact Copyright</b>: https://creativecommons.org/licenses/by-nc-sa/4.0/</p><p><b>Artifact Contact</b>: <a href="mailto:support@computablepublishing.com">support@computablepublishing.com</a></p><p><b>Artifact Author</b>: Brian S. Alper: </p><p><b>CombinationMethod</b>: any-of</p><blockquote><p><b>modifierExtension[http://hl7.org/fhir/StructureDefinition/artifact-status]</b></p></blockquote><p><b>identifier</b>: FEvIR Object Identifier: 179785</p><p><b>type</b>: animal</p><p><b>membership</b>: definitional</p><p><b>name</b>: ComparatorDefinition_Usual_care_pharmacologic_thromboprophylaxis</p><p><b>description</b>: Description: usual-care pharmacologic thromboprophylaxis
Note: Thromboprophylaxis was provided at a dose and duration determined by the treating clinician according to local practice.
Note: Usual-care pharmacological thromboprophylaxis included both intermediate-intensity (in 27%) and prophylactic-intensity dosing (in 72%). Subgroup analyses may be informative to determine if there is a difference related to the intensity used in the control arm of the trial.</p><blockquote><p><b>characteristic</b></p><p><b>CharacteristicDescription</b>: ATTACC comparator arm</p><blockquote><p><b>CharacteristicTiming</b></p><blockquote><p><b>url</b></p><code>contextCode</code></blockquote><p><b>value</b>: Start of trial <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><blockquote><p><b>url</b></p><code>offset</code></blockquote><p><b>value</b>: 0-14</p><blockquote><p><b>url</b></p><code>text</code></blockquote><p><b>value</b>: Up to 14 days or until hospital discharge, whichever comes first. After this period, decisions regarding thromboprophylaxis are at discretion of treating clinician.</p></blockquote><p><b>code</b>: Defined by CodeableConcept <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>value</b>: Standard venous thromboprophylaxis according to local guidelines or usual practice. Dose of chosen agent should not be more than half of the approved therapeutic dose for the treatment of venous thromboembolism. <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>CharacteristicDescription</b>: ACTIV-4a comparator arm</p><blockquote><p><b>CharacteristicTiming</b></p><blockquote><p><b>url</b></p><code>contextCode</code></blockquote><p><b>value</b>: Start of trial <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><blockquote><p><b>url</b></p><code>offset</code></blockquote><p><b>value</b>: 0-14</p><blockquote><p><b>url</b></p><code>text</code></blockquote><p><b>value</b>: Up to 14 days or until hospital discharge, whichever comes first. After this period, decisions regarding thromboprophylaxis are at discretion of treating clinician.</p></blockquote><p><b>code</b>: Defined by CodeableConcept <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>value</b>: Any one of enoxaparin, dalteparin, tinzaparin, fondaparinux, or heparin according to local preference. Dose of agent specified to be consistent with guidelines for low dose thromboprophylaxis. <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>CharacteristicDescription</b>: REMAP-CAP comparator arm</p><blockquote><p><b>CharacteristicTiming</b></p><blockquote><p><b>url</b></p><code>contextCode</code></blockquote><p><b>value</b>: Start of trial <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><blockquote><p><b>url</b></p><code>offset</code></blockquote><p><b>value</b>: 0-14</p><blockquote><p><b>url</b></p><code>text</code></blockquote><p><b>value</b>: Up to 14 days or until hospital discharge, whichever comes first. After this period, decisions regarding thromboprophylaxis are at discretion of treating clinician.</p></blockquote><p><b>code</b>: Defined by CodeableConcept <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>value</b>: Standard venous thromboprophylaxis according to local guidelines or usual practice. Dose of chosen agent should not be sufficient to result in therapeutic anticoagulation. <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>exclude</b>: false</p></blockquote></div>
</text>
<extension
url="http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact">
<valueRelatedArtifact>
<type value="cite-as"/>
<citation
value="ComparatorDefinition: Usual-care pharmacologic thromboprophylaxis [Group]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179785. Revised 2023-11-30. Available at: https://fevir.net/resources/Group/179785. Computable resource at: https://fevir.net/resources/Group/179785."/>
</valueRelatedArtifact>
</extension>
<extension url="http://hl7.org/fhir/StructureDefinition/artifact-title">
<valueString
value="ComparatorDefinition: Usual-care pharmacologic thromboprophylaxis"/>
</extension>
<extension url="http://hl7.org/fhir/StructureDefinition/artifact-url">
<valueUri value="https://fevir.net/resources/Group/179785"/>
</extension>
<extension
url="http://hl7.org/fhir/StructureDefinition/artifact-publisher">
<valueString value="Computable Publishing LLC"/>
</extension>
<extension
url="http://hl7.org/fhir/StructureDefinition/artifact-copyright">
<valueMarkdown
value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
</extension>
<extension url="http://hl7.org/fhir/StructureDefinition/artifact-contact">
<valueContactDetail>
<telecom>
<system value="email"/>
<value value="support@computablepublishing.com"/>
</telecom>
</valueContactDetail>
</extension>
<extension url="http://hl7.org/fhir/StructureDefinition/artifact-author">
<valueContactDetail>
<name value="Brian S. Alper"/>
</valueContactDetail>
</extension>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/combination-method">
<valueCode value="any-of"/>
</extension>
<modifierExtension
url="http://hl7.org/fhir/StructureDefinition/artifact-status">
<valueCode value="active"/>
</modifierExtension>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="ACSN"/>
<display value="Accession ID"/>
</coding>
<text value="FEvIR Object Identifier"/>
</type>
<system value="https://fevir.net"/>
<value value="179785"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<type value="animal"/>
<membership value="definitional"/>
<name
value="ComparatorDefinition_Usual_care_pharmacologic_thromboprophylaxis"/>
<description
value="Description: usual-care pharmacologic thromboprophylaxis
Note: Thromboprophylaxis was provided at a dose and duration determined by the treating clinician according to local practice.
Note: Usual-care pharmacological thromboprophylaxis included both intermediate-intensity (in 27%) and prophylactic-intensity dosing (in 72%). Subgroup analyses may be informative to determine if there is a difference related to the intensity used in the control arm of the trial."/>
<characteristic>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description">
<valueMarkdown value="ATTACC comparator arm"/>
</extension>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-timing">
<extension url="contextCode">
<valueCodeableConcept>
<text value="Start of trial"/>
</valueCodeableConcept>
</extension>
<extension url="offset">
<valueRange>
<low>
<value value="0"/>
</low>
<high>
<value value="14"/>
<unit value="days"/>
<system value="http://unitsofmeasure.org"/>
<code value="d"/>
</high>
</valueRange>
</extension>
<extension url="text">
<valueString
value="Up to 14 days or until hospital discharge, whichever comes first. After this period, decisions regarding thromboprophylaxis are at discretion of treating clinician."/>
</extension>
</extension>
<code>
<text value="Defined by CodeableConcept"/>
</code>
<valueCodeableConcept>
<text
value="Standard venous thromboprophylaxis according to local guidelines or usual practice. Dose of chosen agent should not be more than half of the approved therapeutic dose for the treatment of venous thromboembolism."/>
</valueCodeableConcept>
<exclude value="false"/>
</characteristic>
<characteristic>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description">
<valueMarkdown value="ACTIV-4a comparator arm"/>
</extension>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-timing">
<extension url="contextCode">
<valueCodeableConcept>
<text value="Start of trial"/>
</valueCodeableConcept>
</extension>
<extension url="offset">
<valueRange>
<low>
<value value="0"/>
</low>
<high>
<value value="14"/>
<unit value="days"/>
<system value="http://unitsofmeasure.org"/>
<code value="d"/>
</high>
</valueRange>
</extension>
<extension url="text">
<valueString
value="Up to 14 days or until hospital discharge, whichever comes first. After this period, decisions regarding thromboprophylaxis are at discretion of treating clinician."/>
</extension>
</extension>
<code>
<text value="Defined by CodeableConcept"/>
</code>
<valueCodeableConcept>
<text
value="Any one of enoxaparin, dalteparin, tinzaparin, fondaparinux, or heparin according to local preference. Dose of agent specified to be consistent with guidelines for low dose thromboprophylaxis."/>
</valueCodeableConcept>
<exclude value="false"/>
</characteristic>
<characteristic>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description">
<valueMarkdown value="REMAP-CAP comparator arm"/>
</extension>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-timing">
<extension url="contextCode">
<valueCodeableConcept>
<text value="Start of trial"/>
</valueCodeableConcept>
</extension>
<extension url="offset">
<valueRange>
<low>
<value value="0"/>
</low>
<high>
<value value="14"/>
<unit value="days"/>
<system value="http://unitsofmeasure.org"/>
<code value="d"/>
</high>
</valueRange>
</extension>
<extension url="text">
<valueString
value="Up to 14 days or until hospital discharge, whichever comes first. After this period, decisions regarding thromboprophylaxis are at discretion of treating clinician."/>
</extension>
</extension>
<code>
<text value="Defined by CodeableConcept"/>
</code>
<valueCodeableConcept>
<text
value="Standard venous thromboprophylaxis according to local guidelines or usual practice. Dose of chosen agent should not be sufficient to result in therapeutic anticoagulation."/>
</valueCodeableConcept>
<exclude value="false"/>
</characteristic>
</Group>
IG © 2022+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#1.0.0-ballot based on FHIR 5.0.0. Generated 2023-12-17
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change